Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-23 pm EDT			5-day change	1st Jan Change
3.430 ^USD	-0.87%		-6.03%	+113.04%

Jun. 17	Neuronetics, Inc., Q1 2025 Earnings Call, May 06, 2025
Jun. 10	Neuronetics Announces Clinical Presence At The 2025 Clinical TMS Society Annual Meeting And Progress In Greenbrook's Personalized Care Trial Program	RE

Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published on 05/06/2025 at 07:10

Neuronetics, Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 31.98 million compared to USD 17.42 million a year ago. Sales was USD 31.98 million compared to USD 17.42 million a year ago.

Net loss was USD 12.68 million compared to USD 7.87 million a year ago. Net loss was USD 12.68 million compared to USD 7.87 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.27 a year ago.

Basic loss per share from continuing operations was USD 0.21 compared to USD 0.27 a year ago.

Latest news about Neuronetics, Inc.

Neuronetics, Inc., Q1 2025 Earnings Call, May 06, 2025	Jun. 17
Neuronetics Announces Clinical Presence At The 2025 Clinical TMS Society Annual Meeting And Progress In Greenbrook's Personalized Care Trial Program	Jun. 10	RE
Neuronetics Set To Join Russell 2000® And Russell 3000® Indexes	Jun. 02	RE
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 06	CI
Neuronetics, Inc Announces Retirement of Steve Furlong as Chief Financial Officer, Effective March 31, 2026	May. 06	CI
Neuronetics, Inc. Revises Earnings Guidance for the Full Year 2025	May. 06	CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of 2025	May. 06	CI
Neuronetics Some Non-Cash Revisions Made To Financial Statements Related To Co's Acquisition Of Greenbrook Tms & Shares Outstanding In Q4	Mar. 27	RE
Neuronetics, Inc., Q4 2024 Earnings Call, Mar 04, 2025	Mar. 04
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2025	Mar. 04	CI
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	Mar. 04	CI
Neuronetics Seeks Acquisitions	Feb. 07	CI
Neuronetics Prices Eight Million Share Offering at $2.25 Per Share	Feb. 07	MT
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression	Jan. 29	CI
Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024	Jan. 13	CI
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025	Jan. 13	CI
Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million.	Dec. 08	CI
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024	Nov. 12
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M	Nov. 12	MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 12	CI
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024	Nov. 12	CI
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook	24-10-04	MT
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults	24-09-19	CI
William Blair Downgrades Neuronetics to Market Perform From Outperform	24-08-13	MT
Neuronetics Shares Slump as Q2 Results Fall Below Estimates; Merger Announcement	24-08-12	MT

Chart Neuronetics, Inc.

Duration

Period

STIM: Dynamic Chart

Company Profile

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Employees

716

Sector

Advanced Medical Equipment & Technology

Calendar

Aug. 11 - Q2 2025 Earnings Release (Projected)

More about the company